Abstract:OBJECTIVE To study the complication incidence of 54 patients with chronic HBV infection following their orthotopic liver transplantation (OLT), and factors associated with HBV recurrence and hepatocellular carcinoma (HCC) recurrence or metastasis post-OLT. METHODS The light-microscopic appearance of hepatic allograft biopsies in 54 patients with chronic HBV infection following OLT was examined. The related clinical data were analyzed. The incidence and occurrence time of post-OLT complications were studied. Furthermore, the relationship between recurrent type B viral hepatitis and acute rejection and the relationship among HCC recurrence/metastasis, acute rejection, the tumor diameter, and the portal vein invasion were particularly studied. RESULTS The frequent complications of patients with chronic HBV infection following OLT were acute rejection [38(70.4%); occurrence time: 5-365 d], chronic rejection [ 1(1.9%); occurrence time: 10.7 months],bile duct complications [24(44.4%); occurrence time: 7-940 d], HBV recurrence [7(13.0%); occurrence time: 1-540 d], HCV infection [3(5.6%); occurrence time: 60 d, 60 d, 33 months], CMV infection [8(14.8%); occurrence time: 67-90 d], and HCC recurrence or metastasis [17(31.5%); occurrence time: 2-41 months]. At the end of 1 year post-OLT, 95% of patients with post-hepatitis B cirrhosis were alive; At the end of 3 years post-OLT, 85% of patients with post-hepatitis B cirrhosis were alive. However, at the end of 1 year post-OLT, 67.6% of patients with post-hepatitis B HCC were alive; At the end of 3 years post-OLT, 50% of patients with post-hepatitis B HCC were alive. The number of acute rejection episodes in patients with recurrent HBV infection and that without recurrent HBV infection was (0.86+/-1.46) time/patient and (1.07+/-0.90) time/patient respectively(P>0.05); the number of moderate acute rejection episodes(RAI>or=score 4) in patients with recurrent HBV infection and that without recurrent HBV infection was (0.29+/-0.49) time/patient and (0.50+/-0.63) time/patient(P>0.05); Incidence of patients with >or=3 episodes of acute rejection in patient with recurrent HBV infection and that without recurrent HBV infection was 14.3% and 10.6%(P>0.05). Furthermore, the number of acute rejection episodes in patients with HCC recurrence or metastasis and that without HCC recurrence or metastasis was (1.12+/-0.93) time/patient and (1.06+/-1.39) time/patient respectively(P>0.05); the number of moderate acute rejection episodes(RAI>or=score 4) in patients with HCC recurrence or metastasis and that without HCC recurrence or metastasis was (0.65+/-0.79) time/patient and (0.65+/-1.06) time/patient respectively(P>0.05); Incidence of patients with >or=3 episodes of acute rejection in patient with HCC recurrence or metastasis and that without HCC recurrence or metastasis was 5.9% and 17.6% respectively(P>0.05). The tumor diameter in patients with HCC recurrence or metastasis was (6.72+/-3.40)cm, however, that in patients without HCC recurrence or metastasis was (3.55+/-2.17)cm(P=0.004 7).The incidence of Portal vein invasion in patients with HCC recurrence or metastasis and that without HCC recurrence or metastasis was 68.75% and 33.3% respectively(P=0.006). CONCLUSION There was no significant difference among HBV recurrence and acute rejection post-liver transplantation in patients with chronic HBV infection. There was no significant difference between HCC recurrence and acute rejection. The tumor diameter of patients with HCC recurrence or metastasis was significantly greater than that of no HCC recurrence or metastasis. The portal vein invasion of patients with HCC recurrence or metastasis was significantly frequent than that of no HCC recurrence or metastasis.

High Hepatitis B Virus DNA Level in Serum Before Liver Transplantation Increases the Risk of Hepatocellular Carcinoma Recurrence

Impact of Human Leukocyte Antigen Matching on Hepatitis B Virus Recurrence after Liver Transplantation.

The correlation of HBV infection and HCMV reactive infection after liver transplantation

Pretransplantation HBV DNA load and post liver transplant HCC recurrence in HCC patients undergoing liver transplantation

The Role of Hepatitis B Core-Related Antigen in Predicting Hepatitis B Virus Recurrence after Liver Transplantation.

The Relationship Between Hepatocellular Carcinoma Recurrence and Hepatitis B Virus Recurrence after Liver Transplantation

Prognosis in Liver Transplantation Recipients after Hepatitis B Virus Recurrence.

Post-transplant Hepatitis B Virus Reactivation Impacts the Prognosis of Patients with Hepatitis B-related Hepatocellular Carcinoma: a Dual-Centre Retrospective Cohort Study in China.

Post-transplant HBV reactivation impacts the prognosis of patients with hepatitis B-related hepatocellular carcinoma: a dual-center retrospective cohort study in China

Hepatocellular Carcinoma Recurrence is an Independent Risk Factor for HB Recurrence after Liver Transplantation.

High Hepatitis B Viral Load Predicts Recurrence of Small Hepatocellular Carcinoma after Curative Resection

A Clinicopathologic Study on Complications of Orthotopic Liver Transplantation in 54 Patients with Chronic Hepatitis B Virus Infection

Significance of Hepatitis B Recurrence in Liver Transplantation Recipients

Clinical Analysis of Viral Hepatitis B Recurrence after Liver Transplantation for HBV-related Liver Diseases

Genetic Variations in Plasma Circulating DNA of HBV-Related Hepatocellular Carcinoma Patients Predict Recurrence after Liver Transplantation

HCC Recurrence is an Important Factor of HBV Re-Infection in Liver Transplant Recipients

[Prognosis Analysis of Hepatitis B Virus Recurrence after Liver Transplantation: a Single-Center Study of 38 Cases].

Clinical Analysis of the Recurrence of Hepatitis B Virus-associated Hepatocellular Carcinoma after the Orthotopic Liver Transplantation

HBV is a Risk Factor for Poor Patient Prognosis after Curative Resection of Hepatocellular Carcinoma

Hepatitis B Recurrence After Liver Transplantation: A Single Center Experiences and Review the Literature

Hepatitis B Virus Dna Level Predicts Poor Outcomes In Hepatocellular Carcinoma Patients